Financial Performance and Profitability
Tango Therapeutics reported zero collaboration revenue for the fourth quarter of 2025, a decrease from $5.4 million in the same period of 2024. For the full year 2025, collaboration revenue increased to $62.4 million from $30.0 million in 2024. This annual increase was driven by the recognition of all remaining deferred revenue under the Gilead collaboration during the third quarter of 2025 following the truncation of the agreement. The company posted a fourth-quarter net loss of $38.7 million, or $0.29 per share, widening from a net loss of $30.8 million, or $0.32 per share, in the fourth quarter of 2024. The full-year net loss narrowed to $101.6 million, or $0.87 per share, compared to $130.3 million, or $1.19 per share, in the prior year.
Operating Expenses and Liquidity Position
Research and development expenses for the fourth quarter of 2025 reached $32.1 million, up slightly from $31.3 million in the prior year’s quarter. However, full-year research and development spending declined to $132.2 million from $143.9 million in 2024. This annual decrease resulted from reduced spending on the discontinued TNG908 and TNG348 clinical programs, which was partially offset by increased investments to advance vopimetostat, TNG456, and TNG961. General and administrative expenses were $9.8 million for the fourth quarter and $41.5 million for the full year, reflecting a slight year-over-year decrease primarily driven by lower personnel-related costs. The company ended 2025 with $343.1 million in cash, cash equivalents, and marketable securities, which management expects will fund operations into 2028.
Pipeline Advancements and Corporate Leadership
On the clinical front, Tango Therapeutics is preparing to initiate a pivotal study for vopimetostat monotherapy in second-line MTAP-deleted pancreatic cancer in 2026. The company noted robust ongoing enrollment in a Phase 1/2 combination study of vopimetostat with Revolution Medicines’ RAS(ON) inhibitors for pancreatic and lung cancer. Additionally, a new clinical trial collaboration and supply agreement was established with Erasca to evaluate vopimetostat alongside the pan-RAS molecular glue ERAS-0015. Structurally, Dr. Malte Peters assumed the role of Chief Executive Officer in January 2026, succeeding founding CEO Dr. Barbara Weber, who transitioned to Executive Chair. The company also appointed Philippe Serrano as Chief Regulatory Officer and added Sung Lee to the Board of Directors.